CSIMarket Company Name, Ticker, Industry, else..
 
Marker Therapeutics inc   (MRKR)
Other Ticker:  
 
 
Price: $3.2600 $-0.07 -2.102%
Day's High: $3.5 Week Perf: 2.52 %
Day's Low: $ 3.04 30 Day Perf: -24.54 %
Volume (M): 40 52 Wk High: $ 6.16
Volume (M$): $ 131 52 Wk Avg: $4.05
Open: $3.30 52 Wk Low: $2.44



 Market Capitalization (Millions $) 29
 Shares Outstanding (Millions) 9
 Employees 64
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Marker Therapeutics Inc
Marker Therapeutics Inc. is a clinical-stage biotechnology company that specializes in the development and commercialization of immunotherapies for the treatment of various cancers. The company's patented MultiTAA T-cell therapy technology platform is designed to stimulate the patient's own immune system to target and destroy cancer cells. Marker Therapeutics aims to improve patient outcomes by utilizing personalized immunotherapies that have the potential to be more effective and have fewer side effects than traditional cancer treatments.


   Company Address: 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251 Houston 77021 TX
   Company Phone Number: 400-6400   Stock Exchange / Ticker: NASDAQ MRKR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADCT        12.12% 
FHTX   -4.33%    
NRIX   -3.75%    
RYTM        4.36% 
SUPN        0.06% 
YMAB        2.18% 
• View Complete Report
   



Marker Therapeutics Inc

2. Marker Therapeutics Inc Achieves Promising Improvements in Earnings per Share but Faces Devastating Revenue Slide

Marker Therapeutics Inc (MRKR) has reported its financial results for the period of January to March 31, 2024. The company showed promising improvements in earnings per share (EPS) and reduced its losses compared to the previous year. During this period, MRKR decreased its loss per share to $-0.27, a significant improvement from the $-0.57 loss per share reported in the same period the previous year. Additionally, EPS improved from $-0.32 per share in the previous reporting period.
In terms of revenue, MRKR experienced a sharp decline of -73.723% from $4.73 million in the comparable financial reporting period a year earlier to $1.24 million in the current period. However, sequentially, revenue turned positive from $-2.44 million.
Product Service News

Preliminary Data from Marker Therapeutics APOLLO Study Presented at the 11th Global Summit on Hematologic Malignancies

Published Mon, Apr 8 2024 11:01 AM UTC

The 11th Global Summit on Hematologic Malignancies held in Whistler, BC, Canada, served as a platform for leading experts in the field to discuss and share the latest advancements in the treatment of blood cancers. Among the distinguished speakers was a principal investigator from the prestigious City of Hope National Medical Center, who presented groundbreaking clinical dat...
Marker Therapeutics Inc

Marker Therapeutics Inc Advances Scientific Milestone with Approval of Leading Product Candidate Eldaleucel2.

Financial News Report: Marker Therapeutics Inc Achieves Scientific Milestone Amidst Financial Setbacks
HOUSTON, Jan. 22, 2024 - Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has reached a significant scientific milestone with its leading product candidate receiving crucial approval from both the United States Adopted Name (USAN) Council and the International Nonproprietary Names (INN) Expert Committee. Despite facing financial setbacks, Marker Therapeutics remains dedicated to developing next-generation T cell-based immunotherapies.
The product, MT-601, is a multi-tumor associated antigen-specific (multiTAA) T cell therapy designed to treat patients with lymphoma. The recent endorsements from the USAN and INN highlight the nonproprietary name for MT-601 as
eldaleucel, which streamlines recognition and prescription of this promising immuno-oncology therapy.
Product Service News

Marker Therapeutics Earns Key Approval for MT-601 Under the New Name, Neldaleucel, Amid Financial Setbacks

Published Mon, Jan 22 2024 12:30 PM UTC

HOUSTON, Jan. 22, 2024. Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has achieved a significant scientific milestone, even as it contends with financial setbacks. The advanced biotech firm, dedicated to developing next-generation T cell-based immunotherapies, has announced that its leading product candidate has received crucial approval...
Product Service News

Traversing Bumpy Financial Terrain, Marker Therapeutics Eyes Revolutionary Cancer Treatments with MT-601.

Published Mon, Jan 8 2024 1:25 PM UTC

Marker Therapeutics, a leading bio-pharmaceutical firm, recently announced vital updates and strategic prioritization of its clinical programs with concentrated focus on MT-601 in patients diagnosed with lymphoma. This move is prompted by a series of significant advancements as well as the necessity to tap into promising therapeutic areas that embody the potential to oversha...






Marker Therapeutics Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com